|20th January 2021||Fred E Cohen||20,000||Exercise of derivative||$13.78||$275,600.00|
|30th December 2020||Andrew Schiermeier||1,500||Exercise of derivative||$13.48||$20,220.00|
|17th December 2020||Perry A Karsen||19,000||Exercise of derivative||$15.78||$299,820.00|
|17th December 2020||Perry A Karsen||19,000||Exercise of derivative||$25.98||$493,620.00|
|17th December 2020||Perry A Karsen||21,978||Open or private sale||$52.52||$1,154,284.56|
|17th December 2020||Perry A Karsen||19,000||Exercise of derivative||$14.35||$272,650.00|
|17th December 2020||Perry A Karsen||31,764||Exercise of derivative||$18.00||$571,752.00|
|17th December 2020||Perry A Karsen||45,450||Open or private sale||$53.69||$2,440,210.50|
|17th December 2020||Perry A Karsen||21,336||Open or private sale||$54.33||$1,159,184.88|
|1st December 2020||Jose E Rivera||5,000||Exercise of derivative||$13.88||$69,400.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing.